ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy

Cancer Biology and Therapy

Volumn 4, Issue 2, 2005, Pages 195-202

  Robey, Robert W ^a,b   Steadman, Kenneth ^a   Polgar, Orsolya ^a   Bates, Susan E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Bldg 10 ^*  (United States)

Author keywords

ABCG2; Chlorin; Drug resistance; Photodynamic therapy; Photosensitizer; Porphyrin

Indexed keywords

AMINO ACID; AMINOLEVULINIC ACID; BREAST CANCER RESISTANCE PROTEIN; CHLORIN E6; FUMITREMORGIN C; HEMATOPORPHYRIN; PHEOPHORBIDE; PHEOPHORBIDE A; PHOTOSENSITIZING AGENT; PYROPHEOPHORBIDE A METHYL ESTER; REACTIVE OXYGEN METABOLITE; TETRAKIS(3 HYDROXYPHENYL)CHLORIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL STRAIN HEK293; COMPARATIVE STUDY; CYTOTOXICITY; EXPOSURE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; LIGHT; LUNG ALVEOLUS CELL CARCINOMA; MUTATION; NECROSIS; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; PROTEIN FOLDING; SPECTRAL SENSITIVITY; STRUCTURE ANALYSIS; TRANSPORT KINETICS;

EID: 25144491076     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.2.1440     Document Type: Article

References (47)

1. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998; 90:889-905.
2. Hopper C. Photodynamic therapy: A clinical reality in the treatment of cancer. Lancet Oncol 2000; 1:212-9.
3. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3:380-7.
4. Brown SB, Mellish KJ. Verteporfin: A milestone in opthalmology and photodynamic therapy. Expert Opin Pharmacother 2001; 2:351-61.
5. Sheleg SV, Zhavrid EA, Khodina TV, Kochubeev GA, Istomin YP, Chalov VN, Zhuravkin IN. Photodynamic therapy with chlorin e(6) for skin metastases of melanoma. Photodermatol Photoimmunol Photomed 2004; 20:21-6.
6. Sun X, Leung WN. Photodynamic therapy with pyropheophorbide-a methyl ester in human lung carcinoma cancer cell: Efficacy, localization and apoptosis. Photochem Photobiol 2002; 75:644-51.
7. Jones HJ, Vernon DI, Brown SB. Photodynamic therapy effect of m-THPC (Foscan) in vivo: Correlation with pharmacokinetics. Br J Cancer 2003; 89:398-404.
8. Litle VR, Luketich JD, Christie NA, Buenaventura PO, Alvelo-Rivera M, McCaughan JS, Nguyen NT, Fernando HC. Photodynamic therapy as palliation for esophageal cancer: Experience in 215 patients. Ann Thorac Surg 2003; 76:1687-92, (discussion 1692-3).
9. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol Immunol 2003; 39:1133-6.
10. Kato H, Furukawa K, Sato M, Okunaka T, Kusunoki Y, Kawahara M, Fukuoka M, Miyazawa T, Yana T, Matsui K, Shiraishi T, Horinouchi H. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer 2003; 42:103-11.
11. Baas P, Saarnak AE, Oppelaar H, Neering H, Stewart FA. Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: A phase I/II study. Br J Dermatol 2001; 145:75-8.
12. Capella MA, Capella LS. A light in multidrug resistance: Photodynamic treatment of multidrug-resistant tumors. J Biomed Sci 2003; 10:361-6.
13. Merlin JL, Gautier H, Barberi-Heyob M, Teiten MH, Guillemin F. The multidrug resistance modulator SDZ-PSC 833 potentiates the photodynamic activity of chlorin e6 independently of P-glycoprotein in multidrug resistant human breast adenocarcinoma cells. Int J Oncol 2003; 22:733-9.
14. Li W, Zhang WJ, Ohnishi K, Yamada I, Ohno R, Hashimoto K. 5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells. J Photochem Photobiol B 2001; 60:79-86.
15. Tsai T, Hong RL, Tsai JC, Lou PJ, Ling IF, Chen CT. Effect of 5-aminolevulinic acid-mediated photodynamic therapy on MCF-7 and MCF-7/ADR cells. Lasers Surg Med 2004; 34:62-72.
16. Teiten MH, Bezdetnaya L, Merlin JL, Bour-Dill C, Pauly ME, Dicato M, Guillemin F. Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. J Photochem Photobiol B 2001; 62:146-52.
17. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. . A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95:15665-70.
18. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58:5337-9.
19. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. . Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 1999; 59:8-13.
20. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59:5938-46.
21. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999; 91:429-33.
22. Chen Y-N, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo AT. Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990; 265:10073-80.
23. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001; 7:145-52.
24. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59:4559-63.
25. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD, Kohno S. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001; 280:1216-23.
26. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001; 01:6635-9.
27. Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis and nucleotide trapping by the human ABCG2 multidrug transporter: Modulation of substrate specificity by a point mutation. J Biol Chem 2002; 277:47980-90.
28. Diestra JE, Scheffer GL, Catala I I, Maliepaard M, Schellens JH, Scheper RJ, Germa-Lluch JR, Izquierdo MA. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002; 198:213-9.
29. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99:15649-54.
30. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, Bates SE. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004; 64:1242-6.
31. Hajri A, Wack S, Meyer C, Smith MK, Leberquier C, Kedinger M, Aprahamian M. In vitro and in vivo efficacy of photofrin and pheophorbide a, a bacteriochlorin, in photodynamic therapy of colonic cancer cells. Photochem Photobiol 2002; 75:140-8.
32. Hajri A, Coffy S, Vallat F, Evrard S, Marescaux J, Aprahamian M. Human pancreatic carcinoma cells are sensitive to photodynamic therapy in vitro and in vivo. Br J Surg 1999; 86:899-906.
33. Schneider E, Horton JK, Yang C, Nakagawa M, Cowan KC. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etopside resistance. Cancer Res 1994; 54:152-8.
34. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE. Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003; 89:1971-8.
35. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000; 60:47-50.
36. Preise D, Mazor O, Koudinova N, Liscovitch M, Scherz A, Salomon Y. Bypass of tumor drug resistance by antivascular therapy. Neoplasia 2003; 5:475-80.
37. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004; 279:24218-25.
38. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW. Photodynamic therapy: A means to enhanced drug delivery to tumors. Cancer Res 2003; 63:8126-31.
39. Brown SB, Mellish KJ. Verteporfin: A milestone in opthalmology and photodynamic therapy. Expert Opin Pharmacother 2001; 2:351-61.
40. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002; 1:611-6.
41. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004; 109:238-46.
42. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2004; In press).
43. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004; 76:38-44.
44. Loning M, Diddens H, Kupker W, Diedrich K, Huttmann G. Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer 2004; 100:1650-6.
45. Andersson-Engels S, Canti G, Cubeddu R, Eker C, af Klinteberg C, Pifferi A, Svanberg K, Svanberg S, Taroni P, Valentini G, Wang I. Preliminary evaluation of two fluorescence imaging methods for the detection and the delineation of basal cell carcinomas of the skin. Lasers Surg Med 2000; 26:76-82.
46. Fukuda H, Casas A, Batlle A. Aminolevulinic acid: From its unique biological function to its star role in photodynamic therapy. Int J Biochem Cell Biol 2005; 37:272-6.
47. Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q. 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review). Int J Oncol 2002; 21:577-82.